Summary Imiquimod is an orally active interferon inducer with anti-tumour activity in experimental animals. In this study the tolerability, toxicity and biological effects of daily oral imiquimod administration were investigated in 21 patients with refractory cancer. Patients were treated with doses of 25 mg, 50 mg, 100 mg or 200 mg on a projected 112 day course. Only three patients completed the course, all at the 50 mg dose.
Interferon therapy is well established in oncology, playing an important role in the management of a number of conditions, including hairy cell leukaemia (Quesada et al., 1984) , renal cell cancer (Horoszewicz and Murphy, 1989) and melanoma (von Wussow et al., 1988) . Current regimens require regular administration of interferon by subcutaneous injection using recombinant protein produced in bacteria. Treatment is associated with significant problems of patient acceptability and, frequently, a loss of therapeutic efficacy as a result of the production of neutralising antibodies (Steiss et al., 1988) .
Oral interferon-inducing agents offer theoretical advantages of convenience, prolonged action and the avoidance of immunogenicity. A number of interferon-inducing agents have been investigated, including polyribonucleotide complexes (Hovanessian et al., 1985) , fluorenones (Mayer and Krueger, 1970) , pyrimidones (Nichol et al., 1976) and anthraquinones (Stringfellow et al., 1979) ; none have been shown to induce detectable levels of interferon in man reliably (Dianzani, 1992) . However, it has been shown that imiquimod [1 -(2-methylpropyl)-1 H-imidazo[4,5c]quinolin-4-amine] (MW 240) can induce interferon production in cultured human peripheral blood mononuclear cells (PBMCs) (Weeks and Gibson, 1994) . In experimental animals oral administration of imiquimod leads to interferon production, with peak activity occurring in mice at doses of 30-100 mg kg-and biological activity being detected at doses as low as 3 mg kg-' (Reiter et al., 1994) . In murine tumour models imiquimod has been demonstrated to inhibit growth of several tumour types (Sidky et al., 1992a) and can effect complete regression of some transplantable tumours (Sidky et al., 1990) . The inhibition of imiquimod-induced tumour regression by anti-interferon sera supports an important role for interferon in mediating the actions of imiquimod (Sidky et al., 1992a) . In addition to the interferoninducing actions, imiquimod is postulated to have a direct anti-tumour action via inhibition of tumour angiogenesis (Sidky et al., 1992b) .
The clinical possibilities of imiquimod's interferoninducing actions were first explored in a single-dose safety trial in healthy volunteers. In this study, detectable interferon was induced in two out of six subjects at 200 mg; three of six at 250 mg and of 12 at 300 mg (Wick et al., 1991) . The only significant toxicity observed in this single-dose study were flu-like symptoms that occurred in the majority of the volunteers. Administration of imiquimod to cancer patients on a weekly or twice-weekly schedule has demonstrated biological activity as shown by significant rises in the interferon-related proteins 2-5AS, neopterin and 32M, and interferon production in 17 out of 19 patients within 24 h of a single oral dose of 300 mg (Witt et al., 1993 (Miller et al., 1981) .
Biological responses Serum samples for measurement of interferon, anti-interferon antibodies, neopterin, /32M, 2-5 AS, TNF and IL-1 were collected pretreatment and at 1, 4, 6, 12, 18 and 24 h after the first dose. Subsequently, samples were collected predose and 8 h after dose on day 8 and between days 22 and 49 and days 50 and 112.
Serum interferon concentrations were measured by a bioassay using human lung carcinoma cells (A549) and encephalomyocarditis virus (Grossberg et al., 1986) , and calculated by comparison with an international reference standard. The identity of the interferon as interferon alpha was confirmed by antibody neutralisation studies. The limit for detection of interferon in this assay was 10 IU ml-'. Serum levels of anti-interferon antibodies were determined by incubating dilutions of patients' serum with a known amount of interferon and then assaying as described above. A positive result was taken to be the dilution of serum which would neutralise ten laboratory units of interferon as described by the WHO (1983) .
Serum concentrations of TNF and IL-1 were measured by enzyme-linked immunosorbent assay (ELISA), obtained from Cistron, Pine Brook, NJ, USA. f2M was assayed using a competitive radioimmunoassay obtained from Pharmacia Diagnostics, Piscataway, NJ, USA. Serum neopterin was assayed by a radioimmunoassay employing a kit from DRG International, Mountainside, NJ, USA. The activity of 2-5AS in PBMCs was measured by the incorporation of [3H]ATP into 2',5'-oligoadenylate as described previously (Witt et al., 1993) .
Results

Patient characteristics
Twenty-one patients (nine men, 12 women) with advanced refractory cancer were treated with once-daily oral imiquimod. The patients' ages ranged from 30 to 67 years with a median of 55 years. Eleven patients had metastatic melanoma and ten renal cell cancer. Pretrial therapy comprised surgery in 17 patients, chemotherapy in ten patients, immunotherapy in 12 patients and radiotherapy in four patients. The duration of treatment with daily imiquimod, dose reductions and reasons for discontinuation are shown in Table I . Only three (14%) patients, all in the 50 mg group, completed the treatment. The mean period of treatment decreased from 62 days at 50 mg to 23 days at 100 mg; ten (48%) of the patients withdrew because of disease progression, and five (24%) withdrew because of treatment-related toxicity. Three (14%) further patients did not complete treatment; one patient at 100 mg was lost to followup, one was withdrawn following a myocardial infarction, which was thought not to be treatment related, and at 200 mg one patient was withdrawn for a protocol violation after receiving palliative radiotherapy for bone pain. One dose reduction occurred in the 50 mg group on day 8 as a result of grade 3 lymphopenia, which resolved during further treatment at 25 mg. At 100 mg, three dose reductions occurred between days 8 and 22; all had grade 3 flu-like symptoms, with two having concurrent grade 3 leucopenia. In the 200 mg group, one patient had a dose reduction to 100 mg at day 23 for grade 3 leucopenia.
Efficacy
In the 50 mg dose group, a mixed response was observed in a patient with renal cell cancer and pulmonary metastases. After 1 month of treatment, a 25% reduction in the diameter of the pulmonary metastases was observed, which was 
- (525) The ratios demonstrate the number of patients with detectable levels (> 10 IU ml-') from the total number of patients tested pre and post dose on the sampling days. The range of values is given in parenthesis. 1 -252 ) Mean values are given with range in parenthesis. for the first time, which remained elevated (11 -493 IU ml-') during the remainder of their time on treatment, with, in total, 92 and 112 days' treatment completed respectively. At day 56, another 50 mg patient recorded his first detectable level (60 IU ml-'). In the 100 mg group, one patient had a level of 1862 IU ml-' before the day 8 dose. Eight hours after the day 8 dose, two other patients recorded positive results with levels ranging up to 2160 IU ml-'. Of these three patients, two continued to record elevated levels of interferon when tested at later points in the trial. The highest interferon concentration recorded of 5600 IU ml-' occurred 8 h after the day 22 100 mg dose. In the 200 mg group, only one patient remained on treatment at the day 8 assessment; at this point a value of 25 IU ml-' was recorded.
The effects of imiquimod on the induction of interferonassociated proteins is shown in Table V . Serum levels of 132M did not show any changes within the first 24 h, but when assessed after 22 days' treatment, rises of > 1.5-fold over pretreatment levels were seen in one out of two patients at 25 mg, two out of seven patients at 50 mg, two out of four patients at 100 mg and in the only remaining patient at 200 mg. Similarly, neopterin levels did not change significantly after 24 h but after 22 days' administration increases of >2-fold over pretreatment levels were seen in one out of two patients at 25 mg, two out of seven patients at 50 mg, three out of four patients at 100 mg and in the single 200 mg patient assayed. 2-5AS levels are the most sensitive indicator of induction of the interferon production system and, when assayed at 24 h after the first dose, rises of >2-fold were recorded in one out of three patients at 25 mg, two out of seven patients at 50 mg, three out of six patients at 100 mg and in the only 200 mg patient. When assayed at 22 days, 12 out of a total of 13 patients exhibited more than 2-fold rises in 2-5AS, the sole exception being in the 50 mg dose group. The patient who recorded a disease response did not demonstrate detectable levels of interferon during treatment.
Other biological actions There were no significant changes in levels of TNF or IL-1 at any point in the treatment in any of the patients. Antibodies to interferon were not recorded in any patients before treatment or at discontinuation. There was no apparent association between toxicity and interferon levels or with the levels of the other interferon-related proteins.
Discussion
It is unclear if the linear dose-response relationship that exists for conventional anti-cancer drugs applies to the biological response modifiers. It is possible for these agents that a bell-shaped relationship exists or that a cyclical approach to drug levels or the use of biological agents in combinations may increase efficacy (Creekmore et al., 1991) . The problems associated with subcutaneous administration of interferon, of patient acceptability and immunogenicity, mean that an orally active interferon inducer would have significant advantages for clinical use. Imiquimod has already been demonstrated to induce interferon production in experimental animals (Sidky et al., 1992) , healthy volunteers (Wick et al., 1991) and in cancer patients using weekly or twice-weekly dosing schedules (Witt et al., 1993) . In this study of daily imiquimod, dose-limiting toxicity occurred in 10 of the 21 patients, requiring either dose reduction or discontinuation. In keeping with previous studies using once or twice-weekly imiquimod dosing, the main toxicities observed included flu-like symptoms and nausea and vomiting. With daily imiquimod administration, grade 3 or 4 lymphopenia was seen in 40% of patients receiving 50 mg or more; however, the clinical significance of this degree of lymphopenia in the absence of neutropenia is uncertain. These characteristics, including the dose relationship of the toxicity of imiquimod, are similar to those seen with other clinically tested interferon-inducing agents, particularly bropirimine (Rios et al., 1986) , and probably reflect similar effects on interferon induction.
The biological activity of imiquimod was demonstrated by the significant rises in 2-5AS levels that occurred in 85% of the patients assayed at day 22. Higher drug doses were associated with earlier rises and greater peak levels; in the 25 mg and 50 mg groups there were no changes within the first 24 h, but at 100 mg there was a 2.5-fold increase at this time. #2M and neopterin levels also demonstrated a similar pattern of dose-and time-related increases, with the 100 mg group showing 1.5-fold and 3-fold rises, respectively, at day 22. Despite the evidence for induction of the interferon system at all dose levels, only ten patients recorded detectable levels of systemic interferon. The time taken to produce detectable levels initially was variable ranging from day 8 to day 56; however, the infrequent sampling points do not allow accurate identification of the actual first date of detectable levels. However, once produced, the levels remained elevated throughout the remainder of treatment in all but one patient. This finding argues against the development of hyporesponsiveness, which occurred in the murine trials, although this was seen at much higher dose levels (30 mg kg-'). One mixed clinical response was seen in the trial, which occurred in a patient with renal cell carcinoma after 4 weeks' treatment. However, in this patient there was no systemic interferon detected.
Overall, these results show that imiquimod can achieve some of the desired actions of an oral interferon-inducing agent. Low-dose (25 mg) treatment was well tolerated, with no significant toxicity and, while not producing systemically detectable interferon production, was demonstrated to be immunologically active by the increases in f2M, neopterin and 2-SAS. Higher doses of 50 mg and above showed almost uniform immunological activation and production of interferon in more than 50% of patients, but were associated with significant dose-limiting toxicity. As expected, imiquimod as an inducer of endogenous interferon did not lead to the formation of autoantibodies to interferon.
In clinical trials with the oral interferon-inducing agent, bropirimine, low-level activation of the interferon system, even in the absence of detectable interferon production, was shown to produce some clinical responses in bladder cancer (Rios et al., 1986; Sarosdy et al., 1992) . Therefore, it is possible that imiquimod administered at low doses may develop a role in adjuvant therapy or in long-term anticancer treatments. Before this, the optimum dosing regimen needs to be defined, with further investigations of daily doses of 25-50 mg and the use of variable dosing regimens.
